Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Accumulated Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Accumulated Expenses readings, the most recent being $14.3 million for Q1 2026.

  • On a quarterly basis, Accumulated Expenses rose 62.17% to $14.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $14.3 million, a 62.17% increase, with the full-year FY2025 number at $42.0 million, up 29.87% from a year prior.
  • Accumulated Expenses hit $14.3 million in Q1 2026 for Kiniksa Pharmaceuticals International, down from $42.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $44.7 million in Q1 2024 to a low of $4.9 million in Q1 2022.
  • Median Accumulated Expenses over the past 5 years was $20.9 million (2023), compared with a mean of $23.4 million.
  • Biggest five-year swings in Accumulated Expenses: tumbled 83.72% in 2022 and later soared 376.6% in 2023.
  • Kiniksa Pharmaceuticals International's Accumulated Expenses stood at $11.2 million in 2022, then skyrocketed by 147.28% to $27.7 million in 2023, then rose by 16.69% to $32.4 million in 2024, then increased by 29.87% to $42.0 million in 2025, then plummeted by 66.04% to $14.3 million in 2026.
  • The last three reported values for Accumulated Expenses were $14.3 million (Q1 2026), $42.0 million (Q4 2025), and $17.0 million (Q3 2025) per Business Quant data.